Follow Us On LinkedIn (Link opens in a new window)
Published April 30, 2020
SHARE THIS

Houston Methodist clinicians, researchers, and staff have collaborated on a number of clinical device and research innovations in response to COVID-19.

Their new Engineering Medicine program, EnMed, is in collaboration with Texas A&M University’s engineering and medicine colleges. Together, they’ve been instrumental in rapidly prototyping clinical devices including:

• HMAC: Houston Methodist Aerosol Container
• Personal Protective Pods (PPP) and Collection Pods
• “The Helmet”
• 3D Printable Spacer/Diffusers for Metered Dose Inhalers
• DIY N95 Mask Alternative
• UV Light and Autoclave Mask Sterilization

In addition, researchers are working swiftly to speed up potential therapies through clinical trials and investigational therapies. This includes:

• Convalescent Blood Serum Trial – Houston Methodist was the 1st academic medical center in the nation to infuse donated plasma from a recovered COVID-19 patient into a critically ill patient
• Remdesivir Trial – Houston Methodist was the 5th clinical trial site in the U.S. to offer the antiviral drug Remdesivir as an investigational therapy for COVID-19 patients

Looking to make a difference? Houston Methodist is currently hiring for positions across our health system. Medical response to COVID-19 is pushing the boundaries of health care as we know it. Join our efforts and get a truly unique, career-defining professional experience.

To view our opportunities, visit: www.houstonmethodistcareers.org.

More information about Houston Methodists’ clinical devices and ongoing clinical trials can be found at: https://www.houstonmethodist.org/newsroom/research-and-innovation-as-an-essential-function-amid-the-covid-19-pandemic/

Search
Articles by Category: